You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Atrial Fibrillation (AF) can spontaneously organise to slower and/or more organised atrial rhythms. The Reactive ATP™ (rATP) algorithm delivers atrial antitachycardia pacing (ATP) to terminate an ongoing atrial fibrillation (AF) episode after a programmed interval or when the rhythm organises and/or slows.
aATP† + atrial intervention + MVP arm compared to control arm
The Reactive ATP algorithm studied in the MINERVA trial is available in our dual chamber pacemakers and ICDs, as well as our CRT-Ds and CRT-Ps.
Reactive ATP was referred to as 'aATP' in the MINERVA trial
Model components included group, age, sex, baseline AF, and device type. Frailty model results were consistent with those from Cox proportional hazard models (P< 0.0001 for all).
Follow these steps to turn Reactive ATP on in pacemaker, implantable cardioverter defibrillator (ICD), and cardiac resynchronisation therapy (CRT) devices after lead maturation.
Boriani G, Manolis AS, Tukkie R, et al. Effects of enhanced pacing modalities on health care resource utilization and costs in bradycardia patients: An analysis of the randomized MINERVA trial. Heart Rhythm. June 2015;12(6):1192-1200.
Hudnall H. Reactive Atrial-based Antitachycardia Pacing Therapy to Slow Progression of Atrial Fibrillation. August 2017, Medtronic data on file. Manuscript in preparation.